共 112 条
[1]
Mekaj YH(2015)New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events Ther Clin Risk Manag 11 967-977
[2]
Mekaj AY(2011)Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 883-891
[3]
Duci SB(2011)Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 981-992
[4]
Miftari EI(2013)Treatment of bleeding complications when using oral anticoagulants for prevention of strokes Curr Treat Options Cardiovasc Med 15 288-298
[5]
Patel MR(2009)Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents J Thromb Haemost 7 107-110
[6]
Mahaffey KW(2012)Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors Am J Hematol 87 S141-S145
[7]
Garg J(2012)Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model Anesthesiology 116 94-102
[8]
Granger CB(2013)Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates Thromb Haemost 110 162-172
[9]
Alexander JH(2013)Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis Int J Cardiol 168 4228-4233
[10]
McMurray JJ(2012)Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers Thromb Haemost 108 217-224